Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Satellite Stem Cells and Muscular Dystrophy01:21

Satellite Stem Cells and Muscular Dystrophy

2.0K
Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
2.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Identification of CaVβ1 Isoforms Required for Neuromuscular Junction Formation and Maintenance.

Cells·2025
Same author

Long-Term Dystrophin Replacement Therapy in Duchenne Muscular Dystrophy Causes Cardiac Inflammation.

JACC. Basic to translational science·2025
Same author

Early Endosome Disturbance and Endolysosomal Pathway Dysfunction in Duchenne Muscular Dystrophy.

The American journal of pathology·2025
Same author

Progressive cardiomyopathy with intercalated disc disorganization in a rat model of Becker dystrophy.

EMBO reports·2024
Same author

Oral administration of plumbagin is beneficial in in vivo models of Duchenne muscular dystrophy through control of redox signaling.

Free radical biology & medicine·2024
Same author

GDF5 as a rejuvenating treatment for age-related neuromuscular failure.

Brain : a journal of neurology·2024

Related Experiment Video

Updated: Jul 11, 2025

The Creation of a Rat Model for Osteosarcopenia via Ovariectomy
04:23

The Creation of a Rat Model for Osteosarcopenia via Ovariectomy

Published on: February 21, 2025

331

[GDF5: a therapeutic candidate for combating sarcopenia].

France Piétri-Rouxel1, Sestina Falcone1, Massiré Traoré1

  • 1Sorbonne Université, INSERM, Institut de Myologie, Centre de Recherche en Myologie, F-75013 Paris, France.

Medecine Sciences : M/S
|November 17, 2023
PubMed
Summary

Researchers explored growth differentiation factor 5 (GDF5) as a potential treatment for sarcopenia, an age-related muscle disease. Studies showed GDF5 protein can preserve muscle mass and strength in aged mice, offering a promising therapeutic avenue.

More Related Videos

In Situ Immunofluorescent Staining of Autophagy in Muscle Stem Cells
08:35

In Situ Immunofluorescent Staining of Autophagy in Muscle Stem Cells

Published on: June 12, 2017

10.2K
CRISPR/Cas9 Technology in Restoring Dystrophin Expression in iPSC-Derived Muscle Progenitors
07:44

CRISPR/Cas9 Technology in Restoring Dystrophin Expression in iPSC-Derived Muscle Progenitors

Published on: September 14, 2019

8.4K

Related Experiment Videos

Last Updated: Jul 11, 2025

The Creation of a Rat Model for Osteosarcopenia via Ovariectomy
04:23

The Creation of a Rat Model for Osteosarcopenia via Ovariectomy

Published on: February 21, 2025

331
In Situ Immunofluorescent Staining of Autophagy in Muscle Stem Cells
08:35

In Situ Immunofluorescent Staining of Autophagy in Muscle Stem Cells

Published on: June 12, 2017

10.2K
CRISPR/Cas9 Technology in Restoring Dystrophin Expression in iPSC-Derived Muscle Progenitors
07:44

CRISPR/Cas9 Technology in Restoring Dystrophin Expression in iPSC-Derived Muscle Progenitors

Published on: September 14, 2019

8.4K

Area of Science:

  • Gerontology and Musculoskeletal Research
  • Molecular Biology and Protein Therapeutics

Context:

  • Sarcopenia affects 10-16% of individuals over 65, characterized by significant muscle mass and strength decline.
  • Current understanding of sarcopenia's pathophysiology is limited, with no approved pharmacological treatments available.
  • Age-related muscle loss poses a major health challenge, impacting mobility and quality of life in the elderly.

Purpose:

  • To investigate the therapeutic potential of Growth Differentiation Factor 5 (GDF5) in combating sarcopenia.
  • To elucidate the molecular mechanisms regulating GDF5 expression relevant to muscle health.
  • To evaluate GDF5's efficacy in preserving muscle mass and function in aged animal models.

Summary:

  • The study identified a key molecular pathway controlling GDF5 expression.
  • Therapeutic administration of GDF5 demonstrated significant preservation of muscle mass and strength in aged mice.
  • This research highlights GDF5 as a promising candidate for sarcopenia treatment.

Impact:

  • Provides a novel therapeutic strategy targeting GDF5 for age-related muscle decline.
  • Advances the understanding of molecular mechanisms underlying sarcopenia.
  • Offers potential for improved physical function and quality of life in the aging population.